Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

Elizabeth L. Yanik; Sonia Napravnik; Patrick Ryscavage; Joseph J. Eron; Susan L. Koletar; Richard D. Moore; Anne Zinski; Stephen R. Cole; Peter Hunt; Heidi M. Crane; James Kahn; William C. Mathews; Kenneth H. Mayer; Babafemi O. Taiwo

doi:10.1097/QAI.0b013e31828d69f1

Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

Elizabeth L. Yanik^*, Sonia Napravnik, Patrick Ryscavage, Joseph J. Eron, Susan L. Koletar, Richard D. Moore, Anne Zinski, Stephen R. Cole, Peter Hunt, Heidi M. Crane, James Kahn, William C. Mathews, Kenneth H. Mayer, Babafemi O. Taiwo

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

Original language	English (US)
Pages (from-to)	216-220
Number of pages	5
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	63
Issue number	2
DOIs	https://doi.org/10.1097/QAI.0b013e31828d69f1
State	Published - Jun 1 2013

Keywords

Antiretroviral therapy
Antiretroviral toxicity
Laboratory monitoring

ASJC Scopus subject areas

Infectious Diseases
Pharmacology (medical)

Access to Document

10.1097/QAI.0b013e31828d69f1

Fingerprint Dive into the research topics of 'Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010'. Together they form a unique fingerprint.

Cite this

Yanik, E. L., Napravnik, S., Ryscavage, P., Eron, J. J., Koletar, S. L., Moore, R. D., Zinski, A., Cole, S. R., Hunt, P., Crane, H. M., Kahn, J., Mathews, W. C., Mayer, K. H., & Taiwo, B. O. (2013). Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010. Journal of Acquired Immune Deficiency Syndromes, 63(2), 216-220. https://doi.org/10.1097/QAI.0b013e31828d69f1

Yanik, Elizabeth L. ; Napravnik, Sonia ; Ryscavage, Patrick ; Eron, Joseph J. ; Koletar, Susan L. ; Moore, Richard D. ; Zinski, Anne ; Cole, Stephen R. ; Hunt, Peter ; Crane, Heidi M. ; Kahn, James ; Mathews, William C. ; Mayer, Kenneth H. ; Taiwo, Babafemi O. / Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010. In: Journal of Acquired Immune Deficiency Syndromes. 2013 ; Vol. 63, No. 2. pp. 216-220.

@article{568ae4d569b24d9ca5992e0ed5d7e4e6,

title = "Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010",

abstract = "We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.",

keywords = "Antiretroviral therapy, Antiretroviral toxicity, Laboratory monitoring",

author = "Yanik, {Elizabeth L.} and Sonia Napravnik and Patrick Ryscavage and Eron, {Joseph J.} and Koletar, {Susan L.} and Moore, {Richard D.} and Anne Zinski and Cole, {Stephen R.} and Peter Hunt and Crane, {Heidi M.} and James Kahn and Mathews, {William C.} and Mayer, {Kenneth H.} and Taiwo, {Babafemi O.}",

year = "2013",

month = jun,

day = "1",

doi = "10.1097/QAI.0b013e31828d69f1",

language = "English (US)",

volume = "63",

pages = "216--220",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

Yanik, EL, Napravnik, S, Ryscavage, P, Eron, JJ, Koletar, SL, Moore, RD, Zinski, A, Cole, SR, Hunt, P, Crane, HM, Kahn, J, Mathews, WC, Mayer, KH & Taiwo, BO 2013, 'Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010', Journal of Acquired Immune Deficiency Syndromes, vol. 63, no. 2, pp. 216-220. https://doi.org/10.1097/QAI.0b013e31828d69f1

Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010. / Yanik, Elizabeth L.; Napravnik, Sonia; Ryscavage, Patrick; Eron, Joseph J.; Koletar, Susan L.; Moore, Richard D.; Zinski, Anne; Cole, Stephen R.; Hunt, Peter; Crane, Heidi M.; Kahn, James; Mathews, William C.; Mayer, Kenneth H.; Taiwo, Babafemi O.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 63, No. 2, 01.06.2013, p. 216-220.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

AU - Yanik, Elizabeth L.

AU - Napravnik, Sonia

AU - Ryscavage, Patrick

AU - Eron, Joseph J.

AU - Koletar, Susan L.

AU - Moore, Richard D.

AU - Zinski, Anne

AU - Cole, Stephen R.

AU - Hunt, Peter

AU - Crane, Heidi M.

AU - Kahn, James

AU - Mathews, William C.

AU - Mayer, Kenneth H.

AU - Taiwo, Babafemi O.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

AB - We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

KW - Antiretroviral therapy

KW - Antiretroviral toxicity

KW - Laboratory monitoring

UR - http://www.scopus.com/inward/record.url?scp=84879817835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879817835&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31828d69f1

DO - 10.1097/QAI.0b013e31828d69f1

M3 - Article

C2 - 23446495

AN - SCOPUS:84879817835

VL - 63

SP - 216

EP - 220

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -

Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this